Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.
Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK)
Pijpe A, Andrieu N, Easton DF, Kesminiene A, Cardis E, et. al. and collaborators from GENEPSO; EMBRACE; HEBON.
BMJ. 2012 Sep 6;345:e5660. doi: 10.1136/bmj.e5660.
Estimated Risk of Radiation-Induced Breast Cancer From Mammographic Screening for Young BRCA Mutation Carriers
Amy Berrington de Gonzalez, Christine D. Berg, Kala Visvanathan, Mark Robson. Journal of the National Cancer Institute. Vol. 101, Number 3, p. 205 - 209. Feb 2009.
ACR Appropriateness Criteria Breast Cancer Screening.
Mainiero MB, Lourenco A, Haffty, BG, et. al. J Am Coll Radiol. 2016 Nov;13(11S):R45-R49.
Long-term results of screening with magnetic resonance imaging in women with BRCA mutations
Passaperuma K, Warner E, Causer PA, Hill KA, Messner S, Wong JW, Jong RA, Wright FC, Yaffe MJ, Ramsay EA, Balasingham S, Verity L, Eisen A, Curpen B, Shumak R, Plewes DB, Narod SA.
Br J Cancer. 2012 Jun 26;107(1):24-30. doi: 10.1038/bjc.2012.204. Epub 2012 May 15.
Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging
Warner E, Hill K, Causer P, Plewes D, Jong R, Yaffe M, Foulkes WD, Ghadirian P, Lynch H, Couch F, Wong J, Wright F, Sun P, Narod SA.
J Clin Oncol. 2011 May 1;29(13):1664-9. doi: 10.1200/JCO.2009.27.0835. Epub 2011 Mar 28.
Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the high breast cancer risk italian 1 study): final results
Sardanelli F, Podo F, Santoro F, Manoukian S, Bergonzi S, Trecate G, Vergnaghi D, Federico M, Cortesi L, Corcione S, Morassut S, Di Maggio C, Cilotti A, Martincich L, Calabrese M, Zuiani C, Preda L, Bonanni B, Carbonaro LA, Contegiacomo A, Panizza P, Di Cesare E, Savarese A, Crecco M, Turchetti D, Tonutti M, Belli P, Maschio AD; High Breast Cancer
Risk Italian 1 (HIBCRIT-1) Study.
Invest Radiol. 2011 Feb;46(2):94-105. doi: 10.1097/RLI.0b013e3181f3fcdf.
U.S. Food and Drug Administration (FDA). FDA Safety Communication: Breast cancer screening - Thermography is not an alternative to mammography
The Food and Drug Administration (FDA) says mammography— an X-ray of the breast—is still the most effective way of detecting breast cancer in its earliest, most treatable stages. The agency has sent several warning letters to health care providers and a thermography manufacturer who claim that the thermal imaging can take the place of mammography.